Report Materials
We identified actions that Washington has taken, using Federal funds for improving prescription drug monitoring programs (PDMPs), to achieve program goals toward improving safe prescribing practices and preventing prescription drug abuse and misuse. As of July 2018, Washington had completed some of the activities it proposed for the Centers for Disease Control and Prevention (CDC) grant to enhance and maximize its PDMP. Specifically, of the 11 activities proposed for the audit period (March 1, 2016, through August 31, 2017), 6 were completed, and the remaining 5 were partially completed.
Washington complied with Federal requirements for submitting its Federal Financial Report and Annual Performance Report and publicly reporting the five CDC-directed indicators (required for awardees using PDMPs for public health surveillance).
This report contains no recommendations.
Notice
This report may be subject to section 5274 of the National Defense Authorization Act Fiscal Year 2023, 117 Pub. L. 263.